Double Bond Pharmaceutical has been granted Eurostars funding for development a new product for treatment of pneumonia
A consortium consisted of Double Bond Pharmaceutical together with Karolinska Institute and international partnering SMEs from France has been granted a Eurostars funding. The project has a work name Belopenem and will be focused on developing a novel antibiotic formulation that targets the lung after a simple i.v. injection. The aim of the project is thus to develop a novel and more effective treatment of pneumonia based on Double Bond Pharmaceutical's drug-delivery technology BeloGal®. The project will be conducted for 2 years with the start in November 2018 and result in a fully